Head-to-head · WeighScore
Alan Meds vs Harmon.Health
By GLP-1 ScorecardUpdated
Score comparison
Harmon.Health has the higher recorded score — 74/100 to 65.7/100.
Harmon.Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Harmon.Health sells compounded semaglutide and tirzepatide at one price for every dose, plus dissolving tablets and the brand Wegovy pill, but its site links to no published terms.
Before you choose
Before comparing the headline prices, the Alan Meds review and the Harmon.Health review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Alan Meds vs Idgie Health and Alloy vs Harmon.Health compare each of them with another graded program, and the list of alternatives to Alan Meds ranks the programs closest to Alan Meds on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the GoodLife Health review covers one graded close to these two, at 69.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Alan Meds | Harmon.Health |
|---|---|---|
| WeighScore | 65.7/100 | 74/100 |
| Grade | C | C |
| Site position | #231 | #72 |
| Semaglutide | $158/mo equivalent (2-month upfront promotion, compounded) | $149/mo (month-to-month; $389 billed quarterly or $1,249 yearly, same price at every dose, compounded) |
| Tirzepatide | $325/mo equivalent (6-month upfront plan, compounded) | $199/mo (month-to-month; $499 billed quarterly or $1,599 yearly, same price at every dose, compounded) |
| Coverage | Eligibility depends on state, prescription and pharmacy | All states except Mississippi |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Site position #231 · C
FDAWarning letter issued to Alan Health Technologies Inc. dba Alan in February 2026. See the FDA warning-letter database.
Strengths
- Advertised compounded injection pricing stays the same across doses
- Online care with a choice of injection and sublingual preparations
- Outside-pharmacy choice described; separate charges may apply
- Public catalog lists branded Wegovy and Zepbound options
What to consider
- Lowest compounded price labels require upfront multi-month payment
- First renewal may process early; cancel before the actual processing deadline
- Unused subscription periods are not refundable under the ordinary terms
- Rejection-refund promise differs from broader medical-consent wording
Site position #72 · C
Strengths
- Same price at every dose, with quarterly and yearly plans
- Offers injections, dissolving tablets and the brand Wegovy pill
- Serves every state except Mississippi
What to consider
- The Terms of Service, telehealth consent and privacy notice links in the footer lead nowhere
- Neither the prescribing physicians nor the pharmacies are named
- Introductory prices run until December 1, 2026, and some prices depend on a separate club membership
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.